Published: Guidance, quality standards and advice

Skip to filtersSkip to results

Skip to results

Keyword or reference number

Keyword or reference number

Last updated date

Last updated date

Type

Type

Guidance programme

Showing 1 to 32 of 32

TitleReference numberPublishedLast updated
Enfortumab vedotin with pembrolizumab for untreated unresectable or metastatic urothelial cancer when platinum-based chemotherapy is suitableTA1097
Pembrolizumab with carboplatin and paclitaxel for untreated primary advanced or recurrent endometrial cancerTA1092
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancerTA1037
Pembrolizumab with chemotherapy before surgery (neoadjuvant) then alone after surgery (adjuvant) for treating resectable non-small-cell lung cancerTA1017
Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced oesophageal and gastro-oesophageal junction cancerTA737
Pembrolizumab with platinum- and fluoropyrimidine-based chemotherapy for untreated advanced HER2-negative gastric or gastro-oesophageal junction adenocarcinomaTA997
Pembrolizumab with trastuzumab and chemotherapy for untreated locally advanced unresectable or metastatic HER2-positive gastric or gastro-oesophageal junction adenocarcinomaTA983
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphomaTA540
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma in people 3 years and overTA967
Pembrolizumab with gemcitabine and cisplatin for untreated advanced biliary tract cancer (terminated appraisal)TA966
Pembrolizumab plus chemotherapy with or without bevacizumab for persistent, recurrent or metastatic cervical cancerTA939
Pembrolizumab for previously treated endometrial, biliary, colorectal, gastric or small intestine cancer with high microsatellite instability or mismatch repair deficiencyTA914
Pembrolizumab with lenvatinib for previously treated advanced or recurrent endometrial cancerTA904
Lenvatinib with pembrolizumab for untreated advanced renal cell carcinomaTA858
Pembrolizumab for neoadjuvant and adjuvant treatment of triple-negative early or locally advanced breast cancerTA851
Pembrolizumab for adjuvant treatment of resected stage 2B or 2C melanomaTA837
Pembrolizumab for adjuvant treatment of renal cell carcinomaTA830
Pembrolizumab plus chemotherapy for untreated, triple-negative, locally recurrent unresectable or metastatic breast cancerTA801
Pembrolizumab for treating relapsed or refractory classical Hodgkin lymphoma after stem cell transplant or at least 2 previous therapiesTA772
Pembrolizumab with carboplatin and paclitaxel for untreated metastatic squamous non-small-cell lung cancerTA770
Pembrolizumab for adjuvant treatment of completely resected stage 3 melanomaTA766
Pembrolizumab for untreated metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiencyTA709
Pembrolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapyTA692
Pembrolizumab with pemetrexed and platinum chemotherapy for untreated, metastatic, non-squamous non-small-cell lung cancerTA683
Pembrolizumab for untreated PD-L1-positive, locally advanced or metastatic urothelial cancer when cisplatin is unsuitable (terminated appraisal)TA674
Pembrolizumab for untreated metastatic or unresectable recurrent head and neck squamous cell carcinomaTA661
Pembrolizumab with axitinib for untreated advanced renal cell carcinomaTA650
Pembrolizumab for treating recurrent or metastatic squamous cell carcinoma of the head and neck after platinum-based chemotherapy (terminated appraisal)TA570
Pembrolizumab for untreated PD-L1-positive metastatic non-small-cell lung cancerTA531
Pembrolizumab for treating PD-L1-positive non-small-cell lung cancer after chemotherapyTA428
Pembrolizumab for treating advanced melanoma after disease progression with ipilimumabTA357
Pembrolizumab for advanced melanoma not previously treated with ipilimumabTA366

Results per page

  1. 10
  2. 25
  3. 50
  4. All